



Kite Pharmaceuticals, Inc.  
Investor Relations Department  
2225 Colorado Ave  
Santa Monica, CA 90404  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: KITE**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 109.89                     |
| Trade Time:   | 4:00 PM ET<br>Jul 20, 2017 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 39.82 - 110.08             |
| Volume        | N/A                        |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jul 20, 2017*

[Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma \(NHL\) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute](#)

*Jun 28, 2017*

[U.S. Patent Office to Confirm Kite's Seminal Eshhar CAR-T Patent](#)

*Jun 27, 2017*

[Kite Named to the MIT Technology Review's Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy](#)

*Jun 6, 2017*

[Kite to Present at June 2017 Investor Conferences](#)

*Jun 5, 2017*

[Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia](#)

### Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Feb 28, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 9, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)